Prophylaxis regimens for PJP are well established for HIV‐infected patients with T‐helper cell count (CD4+) less than 200 cells/mm3 and for patients taking high doses of corticosteroids; however, the indication for anti‐Pneumocystis prophylaxis is less clear in other immunosuppressed patient populations.2, 6. Here, CD4 is linked to pneumocystosis.